Talk:Roivant Sciences

This is the talk page for discussing improvements to the Roivant Sciences article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Archives: 1: 152 days

Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent.

This article is rated Start-class on Wikipedia's content assessment scale.
It is of interest to multiple WikiProjects.

Companies Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

50.75.206.4 (talk · contribs) has been paid by Roivant Sciences. Disclosed here
FinalFrontier.003 (talk · contribs) has been paid by Roivant Sciences on their behalf. Freelancer; disclosed here

Removing the word "reportedly"[edit]

This edit request by an editor with a conflict of interest has now been answered.

Since the deal between Sumitomo Dainippon and Roivant closed on December 30, 2019, I am requesting that the word "reportedly" be removed from the last sentence in the Subsidiaries section where it says "In October 2019, Roivant agreed to sell five of its subsidiaries, Myovant, Urovant, Enzyvant, Altavant and Spirovant — in addition to a greater than 10% share in itself — to Sumitomo Dainippon Pharma, reportedly for US$3 billion dollars." Coverage of the deal can be found here and here and here. Thank you for your consideration, FinalFrontier.003 (talk) 09:58, 5 January 2020 (UTC)[reply]

Done Spintendo 16:03, 5 January 2020 (UTC)[reply]

Readability and Promotional language[edit]

It's hard to even tell what this company does with this language, full of jargon and overly promotional language. Does anyone have any info on what pharmaceuticals they sell? This currently reads like an investor report. Marleeashton (talk) 09:16, 26 August 2023 (UTC)[reply]